KALEIDO
Live / Registered — Registered (as of 23 Mar 2021)
What this means for you
Registered since 23 Mar 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88369612
- Registration number
- 6301922
- Mark type
- Design + words
- Filed
- 03 Apr 2019
- Published for opposition
- 12 Nov 2019
- Registered
- 23 Mar 2021
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis
Owner
- Kaleido Biosciences, Inc., Lexington, MA, US
- Kaleido Biosciences, Inc., Lexington, MA, US
- Kaleido Biosciences, Inc., Lexington, MA, US
Prosecution history
- 23 Mar 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 23 Mar 2021 — REGISTERED-PRINCIPAL REGISTER
- 16 Feb 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 15 Feb 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 Feb 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 07 Jan 2021 — USE AMENDMENT FILED
- 27 Jan 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 Jan 2021 — TEAS STATEMENT OF USE RECEIVED
- 09 Jul 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jul 2020 — SOU EXTENSION 1 GRANTED
- 07 Jul 2020 — SOU EXTENSION 1 FILED
- 07 Jul 2020 — SOU TEAS EXTENSION RECEIVED
- 07 Jan 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Nov 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Nov 2019 — PUBLISHED FOR OPPOSITION